Weight Management Drugs

• Nonalcoholic steatohepatitis (NASH) - Aug 01, 2024
• Wegovy (semaglutide) PA Update - Aug 01, 2024
• Semaglutide Prior Authorization Update - Jun 06, 2024

• Drugs for Weight Management - Apr 04, 2024
• New Drug Evaluation: Belviq (lorcaserin hydrochloride), Qsymia (phentermine and topiramate extended release) - Nov 29, 2012

• January 2025 - Off-label Uses of GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists
• October 2024 - New and Emerging Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) in Adults
• July 2024 - Lifestyle Modifications for Obesity: Recommendations and Benefits

• September 2023 - An Update in Weight Loss Therapies - Including FDA Approved GLP-1 Receptor Agonists
• November 2015 - Obesity and Related Sequelae: Are Medications the Answer?
• December 2012 - The Future of Newer Obesity Medications

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.